Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy

被引:11
|
作者
Eitel, Tamara [1 ]
Zeiner, Kim Nikola [1 ]
Assmus, Katharina [1 ]
Ackermann, Hanns [2 ]
Zoeller, Nadja [1 ]
Meissner, Markus [1 ]
Kaufmann, Roland [1 ]
Kippenberger, Stefan [1 ]
Valesky, Eva Maria [1 ]
机构
[1] Goethe Univ Frankfurt, Dept Dermatol Venereol & Allergol, Frankfurt, Germany
[2] Goethe Univ Frankfurt, Dept Biostat & Math Models, Frankfurt, Germany
来源
WORLD ALLERGY ORGANIZATION JOURNAL | 2021年 / 14卷 / 05期
关键词
Hymenoptera venom allergy; Immunotherapy; Sting challenge; Quality of life; DEBILITATING BELIEFS; EMOTIONAL DISTRESS; HOSPITAL ANXIETY; DEPRESSION SCALE; INSECT; EPIDEMIOLOGY; VERSION; HADS;
D O I
10.1016/j.waojou.2021.100536
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: An experienced life-threating anaphylactic reaction to hymenoptera venom can sustainably impair patients' quality of life (QoL). Besides carrying emergency medication, venom specific immunotherapy (VIT) exists as a causal treatment of allergy. Objective: This study aimed to examine QoL, anxiety, depression, and physical and mental health in patients allergic to hymenoptera venom before and during VIT and the impact of a tolerated sting challenge (SC). Methods: Between July 2017 and August 2017, 142 patients with venom allergy were analyzed using validated questionnaires as the: Vespid Allergy Quality for Life Questionnaire" (VQLQ-d), the "Hospital Anxiety and Depression Scale" (HADS-D) and the "Short Form 36" (SF-36).To evaluate the impact of VIT and SC on the QoL, patients were divided into 3 groups: (A) VIT and tolerated SC (n =45), (B) VIT before carrying out SC (n = 73), and (C) therapy-na & iuml;ve before VIT (n = 20). Further parameters like gender, age, insect species, and severity of the anaphylactic reaction were assessed. Results: A significant correlation between the health-related QoL and the parameters of gender and state of treatment was seen. Especially male patients, as well as patients allergic to yellow jacket venom, benefit from a SC in terms of a significant increase in their QoL. In the total study cohort, a clear trend was observed towards a higher QoL in patients under VIT who tolerated a SC. Overall, neither the patients' age nor the insect species exerted a relevant influence on QoL, depression or anxiety. However, women showed a lower QoL combined with higher anxiety and depression scores than men. Conclusion: Immunotherapy leads to an improved QoL, which can be further increased by a SC. A tolerated SC conceivably reassures the patients by objectifying the treatment success. Female patients appear to have a stronger impaired QoL per se. Taken together, a SC can be performed during VIT to strengthen the patients' QoL.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] The sting challenge test in patients with hymenoptera immunotherapy treatment
    Galvez Lozano, J.
    Anguita Carazo, J.
    Mayorgas Costoya, R.
    Saenz de San Pedro Morera, B.
    Palacios Colom, L.
    ALLERGY, 2009, 64 : 342 - 343
  • [22] Ultrarush immunotherapy in patients with Hymenoptera venom allergy -: Reply
    Brehler, R
    Luger, T
    Kütting, B
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (05) : 928 - 929
  • [23] Insect-sting challenge in patients with hymenoptera venom allergy Polish Allergy Society Expert Group Position Paper
    Nittner-Marszalska, Marita
    Bant, Andrzej
    Bodzenta-Lukaszyk, Anna
    Breborowicz, Anna
    Cichocka-Jarosz, Ewa
    Jassem, Ewa
    Kuna, Piotr
    Kruszewski, Jerzy
    Rogala, Barbara
    Szymanski, Wieslaw
    Tworek, Damian
    Wilde, Jerzy
    Zakrzewska, Magdalena
    Zakrzewski, Aleksander
    ALERGIA ASTMA IMMUNOLOGIA, 2010, 15 (03): : 134 - 138
  • [24] Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses
    Ruëff, F
    Wenderoth, A
    Przybilla, B
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 108 (06) : 1027 - 1032
  • [25] Sublingual immunotherapy with venom is not recommended for patients with Hymenoptera venom allergy Reply
    Passalacqua, Giovanni
    Severino, Maurizio G.
    Cortellini, Gabriele
    Bonadonna, Patrizia
    Macchia, Donatella
    Canonica, Walter G.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (01) : 273 - 273
  • [26] HONEYBEE VENOM ALLERGY - RESULTS OF A STING CHALLENGE 1 YEAR AFTER STOPPING SUCCESSFUL VENOM IMMUNOTHERAPY IN 86 PATIENTS
    MULLER, U
    BERCHTOLD, E
    HELBLING, A
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1991, 87 (03) : 702 - 709
  • [27] Depot extracts for rush venom immunotherapy A new therapeutic opportunity for Hymenoptera sting allergy
    Pucci, Stefano
    Ciccarelli, Fedra
    De Pasquale, Tiziana
    Illuminati, Ilenia
    D'Alo, Simona
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (03) : 376 - 377
  • [28] Evaluation of the cytokine response induced by specific allergen immunotherapy in patients with hymenoptera venom allergy
    Armisen, M.
    Cruz Carmona, M. J.
    Vidal, C.
    ALLERGY, 2023, 78
  • [29] Field sting reactions in patients receiving Hymenoptera venom immunotherapy: Real-life experience
    Sozener, Zeynep Celebi
    Kendirlinan, Resat
    Cerci, Pamir
    Aydin, Omur
    Mungan, Dilsad
    Bavbek, Sevim
    Demirel, Yavuz
    Misirligil, Zeynep
    Sin, Betul Ayse
    ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY, 2023, 41 (03): : 186 - 192
  • [30] Lifetime Immunotherapy for Hymenoptera Venom Allergy?
    von Kieseritzky, Kathrin
    ALLERGO JOURNAL, 2016, 25 (07) : 51 - 51